Lilly reports positive Phase 3 results for modified Kisunla dosing

jetcityimage/iStock Editorial via Getty Images Eli Lilly ( NYSE: LLY ) reported positive results from a Phase 3 study evaluating a modified dosing regimen for its Alzheimer’s drug Kisunla, which could support a potential label update for the product. The Phase 3 study showed that shifting one vial.